Hellesnes R, Kvammen O, Myklebust TA, et al. - Researchers determined the risk of second cancer (SC) in testicular cancer survivors (TCS) treated in the cisplatin era, by analyzing full information on total treatment burden. Using the Cancer Registry of Norway, 5,625 1-year TCS diagnosed 1980-2009 were selected. Participants were observed over a median duration of 16.6 years. Overall 651 non-germ cell SCs were developed by 572 TCS. A raised SC risk was reported following surgery only, with site-specific elevated risks of thyroid cancer and melanoma. The risks for cancers of the small intestine, bladder, kidney and lung were increased 2.0-3.7-fold following chemotherapy (CT). Following ≥ 2 cycles of cisplatin-based CT, a 1.6-2.1-fold elevated risk of SC was observed. A link of radiotherapy (RT) with 1.5-4.4-fold raised risks for cancers of the stomach, small intestine, liver, pancreas, lung, kidney and bladder, was noted. Risks of haematological malignancies increased following combined CT and RT. Overall, an increased risk of developing SC was observed for TCS treated in the cisplatin era, this was especially noted after therapy with cisplatin-based CT and/or RT.